Tuesday, October 4, 2022


Biotechnology News Magazine

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes

Latest Posts

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Araris Biotech Closes $24 Million Financing Round

Araris Biotech notes the proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer toward clinical development.

FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with lower risk transfusion-dependent myelodysplastic syndromes (MDS).

“We are very pleased to complete enrollment of this Phase 3 study of roxadustat for the treatment of anemia in patients with lower risk MDS,” said Mark Eisner, M.D, M.P.H, Chief Medical Officer, FibroGen. “Patients living with MDS have limited treatment options for their anemia, and MATTERHORN evaluates roxadustat as a potential new treatment that can reduce the burden of blood transfusions. On behalf of the entire study team, we would like to extend our gratitude to the patients, caregivers, investigators, and study staff for their commitment to this study.”

A total of one-hundred forty-one (141) subjects have been enrolled in MATTERHORN, a Phase 3, double-blind placebo-controlled study investigating the efficacy and safety of roxadustat for treatment of anemia in patients with lower risk transfusion-dependent myelodysplastic syndromes. The primary endpoint of the study is transfusion independence for ≥ 56 consecutive days in the first 28 weeks of treatment. The main secondary endpoint is reduction of red blood cell transfusion. Top-line data from the MATTERHORN study is anticipated in 1H 2023. For more information about MATTERHORN please visit www.clinicaltrials.gov (NCT03263091).

About MDS Anemia
Myelodysplastic syndromes (MDS) are a group of disorders characterized by poorly formed or dysfunctional blood cells, resulting in chronic anemia in most patients. Annual incidence rates of MDS are estimated to be 4.9/100,000 adults in the U.S1. Approximately 80% of MDS patients have anemia at the time of diagnosis2 and around 60% of MDS patients will experience severe anemia (hemoglobin <8 g/dL) at some point during the course of their disease3. Lower-risk MDS patients represent approximately 77% of the total diagnosed MDS population4. Anemia in MDS patients is associated with increased risk of cardiovascular complications and the need for blood transfusion5. Transfusion dependent MDS patients suffer higher rates of cardiac events, infections and transformation to acute leukemia, and a decreased overall survival rate when compared with non-transfused patients with MDS, and decreased survival compared to an age-matched elderly population6. In addition, anemia frequently leads to significant fatigue, cognitive dysfunction, and decreased quality of life. Currently, there are few options available for treating anemia in MDS. Patients with MDS typically rely on repeated blood transfusions and administration of ESAs.

About Roxadustat
Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. Roxadustat is in clinical development for anemia of chronic kidney disease (CKD) and anemia associated with myelodysplastic syndromes (MDS), and for chemotherapy-induced anemia (CIA).

Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).  Several other licensing applications for roxadustat have been submitted by partners, Astellas and AstraZeneca to regulatory authorities across the globe, and are currently under review.

Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in territories including Japan, Europe, Turkey, Russia and the Commonwealth of Independent States, the Middle East, and South Africa. FibroGen and AstraZeneca are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in the U.S., China, and other markets not licensed to Astellas.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine